HONG KONG – An Indian pharmaceutical company said it is still exporting its products to Vietnam as usual, disputing reports that it had been one of some four-dozen companies allegedly banned from the growing Southeast Asian market.
TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.
HONG KONG – One of China's largest vaccine makers will become the first to produce a polio vaccine in China after entering into a deal with a Dutch developer.
SHANGHAI – Authorities in Beijing are loosening price controls for a select number of commonly used, low-cost medicines. While few innovative drugs are expected to be affected, the move signals the government is willing to take a step back when necessary in its ongoing efforts to rein in drug costs.
Lupin Ltd., of Mumbai, India, named Theresa Stevens chief corporate development officer for its global operations, with full responsibility for global merger and acquisitions and specialty business strategy.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd., of China, is acquiring Chindex International Inc., of Bethesda, Md., a health care company providing services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics.
TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.
HONG KONG – The CFDA gave the green light to Chongqing Zhifei Biological Products Co. Ltd. (SZ:300122) to launch its joint vaccine against group A and C meningococcus and haemophilus influenzae type B (AC-Hib). Zhifei's subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., developed the vaccine that aims to prevent infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis caused by group A and C meningococcus as well as type b haemophilus influenzae (Hib).
HONG KONG – A Chinese investment company focused on health care has secured a third fund to invest $188 million in pharmaceuticals, medical technology, health care services and biotech companies.
SHANGHAI – At the 4th Annual Biopharma China Congress in Shanghai last week, smaller biotechs and established contract research organizations (CRO) rubbed shoulders with government-funded academics. Meanwhile the China division of Sanofi SA of France was one of the only international companies in attendance.
RSS